SCHEMBL4164963

SCHEMBL4164963

Cc1cc(Nc2cnc(-c3ccc(Cl)cc3Cl)c(N)n2)n[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ CRHR1 P34998 1/20 0.42
▸ AURKA O14965 5/20 0.41
▸ GSK3B P49841 4/20 0.41
▸ PAK4 O96013 3/20 0.39
▸ PLK4 O00444 2/20 0.39
▸ SRC P12931 1/20 0.39
▸ PAK1 Q13153 1/20 0.38
▸ ITK Q08881 1/20 0.38
▸ SCN10A Q9Y5Y9 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ NTRK1 P04629 1/20 0.37
▸ AURKB Q96GD4 1/20 0.37
▸ DPP4 P27487 1/20 0.37
▸ SCN2A Q99250 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4173931 0.91 MEN1 (0.43) MEN1HTTKMT2AHSD17B10AURKA
SCHEMBL4171771 0.89 MEN1 (0.42) MEN1HTTKMT2AHSD17B10AURKA
SCHEMBL4175191 0.87 CHEK1 (0.45) MEN1HTTKMT2AHSD17B10AURKA
SCHEMBL4179012 0.85 MEN1 (0.46) MEN1HTTKMT2AHSD17B10AURKA
SCHEMBL4168909 0.81 IKBKB (0.46) MEN1HTTKMT2AHSD17B10AURKA
SCHEMBL4169281 0.80 MEN1 (0.43) MEN1HTTKMT2AHSD17B10AURKA
SCHEMBL4161742 0.78 ITK (0.44) AURKAGSK3BPAK4PLK4SRC
SCHEMBL4168663 0.78 AURKB (0.43) MEN1HTTKMT2AHSD17B10AURKA
SCHEMBL4171086 0.76 NPC1 (0.41) MEN1HTTKMT2AHSD17B10AURKA
SCHEMBL4166686 0.75 DHODH (0.40) MEN1HTTKMT2AHSD17B10AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US claimed
WO-2009089042-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2009-07-16 — — WO claimed
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH MAP3K1, MAP3K15, MAP3K5 MEN1 3321/4885HTT 1548/4885KMT2A 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback